California-based Dynavax Technologies entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19.

Sunovion Pharmaceuticals Inc. announced that results of a four-week pivotal study (SEP361-201) evaluating the safety and efficacy of SEP-363856 in patients with schizophrenia were published online in the New England Journal of Medicine.

A drug used to treat head lice in humans and parasites in animals demonstrated efficacy against COVID-19 in laboratory tests, and the U.S. Food and Drug Administration is already warning people to not attempt to self-medicate with the drug to treat the novel coronavirus.

A trial in China testing Gilead Sciences Inc.’s antiviral drug remdesivir in those with mild symptoms of COVID-19 was suspended due to a lack of eligible patients, according to a website maintained by the U.S. government.

Cambridge, Massachusetts-based Moderna is one of the first companies to move a vaccine against COVID-19 into clinical trials.

For some time, there has been speculation that glucose metabolism was associated with Alzheimer’s disease, with some researchers going so far as to call Alzheimer’s diabetes type 3. Researchers with the National Institutes of Health’s National Institute on Aging conducted the largest study so far on proteins related to Alzheimer’s and identified proteins and biological processes that regulate glucose metabolism that are associated with Alzheimer’s. The study was published in the journal Nature Medicine.

According to the World Health Organization (WHO), there are more than 70 potential vaccines under development, with three already in clinical trials.

As the world continues to wait for a vaccine against COVID-19, GlaxoSmithKline and Sanofi joined forces to develop an adjuvanted vaccine for COVID-19.

A preliminary analysis of late-stage trial data showed that BeiGene’s investigational checkpoint inhibitor tislelizumab is hitting the mark as a potential first-line treatment in patients with non-squamous non-small cell lung cancer (NSCLC).

Nasal Swab, COVID

Origin, a 3D printing specialist for medical devices, completed clinical trials and validation of the company’s 3D-printed nasopharyngeal swabs for use in COVID-19 test kits.